Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of α1-antitrypsin or the exogenous α1-antitrypsin treatment exhibits an anti-oxidative stress role, evaluated by increased eNOS expression and by decreased MMP9 expression, implicated in HF.
|
31782085 |
2020 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Calpain1 and MMP9 are proteolytic degratory factors that play a major role in cardiomyocyte decline in HF.
|
30353496 |
2019 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Metalloproteinases and their inhibitors, such as MMP9 and TIMP-1, assist in maintaining the extracellular matrix, leading to tissue remodeling observed after HF.
|
31099017 |
2019 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Induction of heart failure in rats has significantly increased circulating NT-proBNP (980 ± 116.71 pg/ml), MMP9 (15.85 ± 0.57 ng/ml), troponin-I (3.09 ± 0.147 ng/ml), CK-MB (31.55 ± 1.69 ng/ml), renin (736 ± 45.8 pg/ml), urea (52.1 ± 1.57 mg/dl), and creatinine (0.92 ± 0.04 mg/dl).
|
31053170 |
2019 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The contractile responses induced by CCh, ATP and EFS were greater in detrusor muscle (DSM) from HF rats. mRNA expression for muscarinic receptors (M2 and M3) was higher in DSM only after 12 weeks of ACF, in addition to MMP9 and TGF-beta.
|
30965053 |
2019 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Specific matrix metalloproteinases (MMP-2, MMP-9) and inflammatory biomarkers (hsCRP, IL-6) were found to be consistently up-regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failure patients.
|
29663512 |
2018 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cardiac function in class III and above, increased NT-proBNP, increased MMP-9 and decreased LVEF were relevant risk factors and independent risk factors for heart failure in patients with different cardiac functions.
|
29904410 |
2018 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
A multivariate Cox proportional hazard model showed that high MMP-9 values were an independent predictor of HF events (hazard ratio, 3.73; 95% confidence interval (CI), 1.03-13.46; P = 0.043).
|
28772055 |
2017 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Patients were in New York Heart Association (NYHA) functional class III or IV heart failure showed a significantly higher MMP9 levels (1,348.0±337.2 <i>vs</i>.
|
28523165 |
2017 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
At the same time MMP-2 and MMP-9 circulating levels can serve as indicators of efficiency of the therapy provided to HF patients, as well as for identification of patients who could profit from particular therapeutic intervention via modification of MMP pathway.
|
28399617 |
2017 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Given that MMP-9 is an AP-1 target gene involved in cardiac remodeling, myocardial dysfunction and progression of heart failure, these findings suggest that miR-146a might be a new and promising therapeutic tool for treating cardiac disorders associated with enhanced inflammation in the heart.
|
26112171 |
2015 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Activated Mmp9 degrades extracellular matrix (ECM) and increases matrix turnover causing cardiac fibrosis that leads to heart failure.
|
25064116 |
2014 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients.
|
17889183 |
2007 |
Heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension.
|
17913382 |
2007 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Decreased GH, decreased IGF-I and increased MMP-9 activities may be possible diagnostic markers in RHD for developing heart failure.
|
16406300 |
2006 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Therefore, mixed adrenoceptor blockade may reduce remodeling in heart failure as a direct consequence of a beta-adrenoceptor-mediated reduction in MMP-9 transcription.
|
16574429 |
2006 |
Heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
|
11342481 |
2001 |